# Illumina, Inc.: Form 10-Q for the period ended Sep 29, 2024

- Company: [Illumina, Inc.](/companies/ilmn.md) (CIK 1110803)
- Form: 10-Q
- Filed: 2024-11-06
- Accepted by EDGAR: Nov 5, 2024, 18:11 ET
- Period: 2024-09-29
- Accession: 0001110803-24-000052
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1110803/000111080324000052/ilmn-20240929.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1110803/000111080324000052/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-09-29.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-07-01 to 2024-09-29 | $1.08bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2024-01-01 to 2024-09-29 | $3.27bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2024-07-01 to 2024-09-29 | $335.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2024-01-01 to 2024-09-29 | $1.14bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2024-07-01 to 2024-09-29 | $745.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2024-01-01 to 2024-09-29 | $2.13bn | us-gaap:GrossProfit |
| Research and development | 3 months, 2024-07-01 to 2024-09-29 | $253.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2024-01-01 to 2024-09-29 | $913.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2024-07-01 to 2024-09-29 | $239.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2024-01-01 to 2024-09-29 | $813.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-07-01 to 2024-09-29 | $741.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-01-01 to 2024-09-29 | −$1.01bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-07-01 to 2024-09-29 | $36.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2024-01-01 to 2024-09-29 | $75.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2024-07-01 to 2024-09-29 | $15.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-01-01 to 2024-09-29 | $44.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-07-01 to 2024-09-29 | $705.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-01-01 to 2024-09-29 | −$1.41bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-07-01 to 2024-09-29 | $4.42 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-01-01 to 2024-09-29 | −$8.86 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-07-01 to 2024-09-29 | $4.43 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-01-01 to 2024-09-29 | −$8.86 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-07-01 to 2024-09-29 | 160,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-01-01 to 2024-09-29 | 159,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-01-01 to 2024-09-29 | $473.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2024-01-01 to 2024-09-29 | $99.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2024-01-01 to 2024-09-29 | $99.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Current assets | at 2024-09-29 | $2.37bn | us-gaap:AssetsCurrent |
| Total assets | at 2024-09-29 | $6.01bn | us-gaap:Assets |
| Current liabilities | at 2024-09-29 | $975.0m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2024-09-29 | $2.13bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1110803/000111080324000052/ilmn-20240929.htm

Filed Nov 6, 2024.
Source: SEC EDGAR, the filing index for accession 0001110803-24-000052. Last ingested by Listed: Nov 14, 2026, 13:59 ET. No prices; not investment advice.
